Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 6
2021 5
2022 3
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N, Ganesan S, Chendamarai E, Palani HK, Venkatraman A, Alex AA, David S, Kumar SP, Radhakrishnan NR, Yasar M, Krishna S, Korula A, Kulkarni U, Janet NB, Balasubramanian P, Mathews V. Balasundaram N, et al. Blood Adv. 2022 Jan 25;6(2):652-663. doi: 10.1182/bloodadvances.2021005300. Blood Adv. 2022. PMID: 34625794 Free PMC article.
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
Kulkarni UP, Selvarajan S, Lionel S, Prakash MA, Palani HK, Balasundaram N, Venkataraman A, Korula A, Devasia AJ, Fouzia NA, Janet NB, Nair SC, Abraham A, Mani T, Lakshmanan J, Arunachalam AK, Balasubramanian P, George B, Mathews V. Kulkarni UP, et al. Blood Cancer J. 2022 Jan 31;12(1):22. doi: 10.1038/s41408-022-00619-3. Blood Cancer J. 2022. PMID: 35102152 Free PMC article. No abstract available.
Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.
Rajamani BM, Benjamin ESB, Abraham A, Ganesan S, Lakshmi KM, Anandan S, Karathedath S, Varatharajan S, Mohanan E, Janet NB, Srivastava VM, Ramachandran Velayudhan S, Kulkarni UP, Devasia AJ, Fouzia NA, Korula A, George B, Srivastava A, Mathews V, Balasubramanian P. Rajamani BM, et al. Sci Rep. 2020 Nov 26;10(1):20640. doi: 10.1038/s41598-020-77140-9. Sci Rep. 2020. PMID: 33244077 Free PMC article.
Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
Ganesan P, Jain H, Bagal B, Subramanian PG, George B, Korula A, Mehra N, Kalaiyarasi JP, Bhurani D, Agrawal N, Ahmed R, Kayal S, Bhattacharyya J, Yanamandra U, Kumar S, Philip CC, John MJ, Nadaraj A, Karunamurthy O, Lakshmanan J, Mathews V, Sengar M. Ganesan P, et al. Br J Haematol. 2021 Apr;193(1):e1-e4. doi: 10.1111/bjh.17268. Epub 2021 Mar 3. Br J Haematol. 2021. PMID: 33656752 Free PMC article. No abstract available.
BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib.
Benjamin ESB, Ravindra N, Rajamani BM, Anandan S, Kausalya B, Veldore V, Mathews V, Velayudhan SR, Balasubramanian P. Benjamin ESB, et al. Leuk Lymphoma. 2021 Jun;62(6):1528-1531. doi: 10.1080/10428194.2021.1872074. Epub 2021 Jan 22. Leuk Lymphoma. 2021. PMID: 33478278 Free PMC article. No abstract available.
Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
Maddali M, Kulkarni UP, Ravindra N, Arunachalam AK, Venkatraman A, Lionel S, Manipadam MT, Devasia AJ, Korula A, Fouzia NA, Abraham A, Srivastava A, George B, Balasubramanian P, Mathews V. Maddali M, et al. Hematol Oncol Stem Cell Ther. 2022 Jun 1;15(2):13-20. doi: 10.1016/j.hemonc.2021.03.002. Hematol Oncol Stem Cell Ther. 2022. PMID: 33789164 Free PMC article.
15 results